Directors and Senior Leadership

Professor Robinson is a practising Endocrinologist and Chair of Research at Sydney’s Royal North Shore Hospital. He is Former Dean of University of Sydney’s Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989.

Ms Ann Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin served as both CFO and Board Director of Siemens Medical Solutions (now Siemens Healthineers), a leading medical technology company with EUR20b in revenues.

Mr David Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne.

Mr Jacob Ma-Weaver was appointed to the Board on 14 August 2026. Mr Ma-Weaver is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Cable Car is the General Partner of Funicular Funds, LP, a hedge fund. Funicular Funds, LP, holds 9.90% of the fully paid ordinary shares in Mayne Pharma. Mr Ma-Weaver served on the Board of ARCA biopharma, Inc. from 2022 until its business combination with Oruka Therapeutics in 2024. Prior to his role at Cable Car, Mr Ma-Weaver was an investment analyst at Amici Capital LLC, where he focused on healthcare. He previously worked as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company. Mr Ma-Weaver received a Bachelor of Arts in Comparative Literature & Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder.

Ms Meghan Rivera was appointed to the Board on 26 June 2026. Ms Rivera, a US resident, brings more than 25 years of experience in the US pharmaceutical industry across multiple therapeutic areas including women’s health.

Laura was appointed as the Company Secretary on 26 March 2020. Laura has been with Mayne Pharma since May 2014 and is an experienced commercial lawyer with more than ten years of experience. Prior to joining Mayne Pharma, Laura was a solicitor at global law firm DLA Piper. Laura holds a BCom (Accounting) degree and LLB (Hons) degree from Monash University and is a Graduate member of the Australian Institute of Company Directors.

Aaron joined Mayne Pharma in July 2022 and brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20b in revenues and 48,000 employees globally. Most recently, he was Senior Vice President - USA Customer Finance with EUR5b in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens, AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence. He has a Bachelor of Science in Finance and Master of Business Administration (MBA) from the University of Central Florida.

Griffin joined Mayne Pharma in August 2026 and is a senior finance executive with extensive experience in global medical technology and healthcare. Prior to Mayne Pharma, Griffin worked at Establishment Labs (NASDAQ: ESTA), a global medical technology company focused on women's health, where he served as Vice President, Operational Finance, leading financial planning, analysis and operational performance across the business.  Prior to Establishment Labs, Mr Buchanan spent over 19 years at Siemens Healthineers (SHL:DE), one of the world's leading medical technology companies, where he held a series of senior finance leadership roles.  Mr Buchanan holds an Executive MBA from Friedrich-Alexander-Universität Erlangen-Nürnberg and a Bachelor of Science, Business Administration, Information Technologies & Operations from the University of New Hampshire's Peter T. Paul College of Business and Economics.

Frank Casty, MD has 30 years of global drug development experience including clinical development, medical and regulatory affairs and pharmacovigilance. In addition to leading numerous NDA/MAA filings across multiple therapeutic areas, he has significant launch and lifecycle management experience and has held several enterprise-wide leadership positions.

Daniel joined Mayne Pharma in 2015, where he led the Dermatology business. In 2026, he moved to DistributeRx as President, bringing over 20 years of experience in the healthcare industry. In his current role, Daniel oversees the full organization, including strategy, operations, sales, marketing, client partnerships, channel and pharmacy management, and analytics. He holds a BA in Economics and an MA in Accounting from the University of North Carolina at Chapel Hill.

Kim joined Mayne Pharma in May 2022 and has more than 20 years of experience covering commercial and IP law, most of which were spent working in the pharmaceutical industry. Prior to joining Mayne Pharma, Kim was Vice President, Business Development Counsel at Alkermes, Inc. Previously, she worked for Novartis for 12 years and at GSK, General Electric and Alston & Bird focusing primarily in the areas of intellectual property, corporate development and patent law. Kim has a BA in Chemistry and BS in Zoology from North Carolina State University. She earned her Juris Doctorate from North Carolina Central University School of Law and is also a registered US Patent Attorney.

Brant joined Mayne Pharma in October 2018 and has more than 25 years of experience in the pharmaceutical industry including more than 15 years at Galderma Laboratories, a leading global dermatology and skin health company. Previously, he was Vice President and General Manager Dermatology at Sandoz US where he was responsible for brand and generic product portfolio with revenues of approximately US$500m.

Tony Ramy joined Mayne Pharma in February 2024 and brought with him more than 25 years of pharmaceutical and CDMO experience across several industry leading organizations. Prior to joining Mayne, he spent 12 years at Novo Nordisk where he launched Ozempic and was a foundational member of the team that created the Obesity Business Unit. Tony worked at AMRI (Curia) as the Senior Director of Business Development for North America where he and his team were responsible for several drug development contacts that are now commercialized across the globe. From a women’s health standpoint, Mr. Ramy spent 13 years in various leadership roles at Organon through the acquisition by Schering-Plough and then Merck. Tony prides himself on leading with a high level of humility and integrity, valuing diverse perspectives, sharing information even when it is difficult, and ensuring his actions are consistent with his words. Tony holds 2 Bachelor of Science Degrees in Human Nutrition and Hotel Management from the University of Massachusetts at Amherst.

Grant joined Mayne Pharma in January 2023 and brings more than 25 years' experience to the role. Grant has held senior leadership positions in FMCG, Food & Beverage industries and the last 8 years in Pharmaceuticals. During this period, he led a significant organisation wide transformation in a large multi-site pharmaceutical operation with approximately 2500 employees and manufacturing revenues in excess of A$122m.

Kate joined Mayne Pharma in July 2026 and brings more than 20 years of experience in Human Resources, having led talent acquisition, total rewards, succession and workforce planning, performance coaching, and organisational change management for several successful IPOs and large multinational biotech companies.  During her career, Kate has held a variety of HR roles with increasing responsibility, most recently as the CHRO of a publicly traded commercial med tech company, Mimedx.  Previously, she was Head of HR for Vaxxinity, a clinical-stage biotech, and Senior Vice President of HR for Viela Bio, a successful biotech start-up spun out of AstraZeneca that was later acquired by Horizon Therapeutics. Earlier in her career, Kate provided HR support to multiple functions within the biologics and small molecule teams at MedImmune/AstraZeneca. Ms Surdez holds a B.A. in History from the University of North Carolina at Wilmington.